+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Validation of international consensus guidelines for the resection of branch duct-type intraductal papillary mucinous neoplasms



Validation of international consensus guidelines for the resection of branch duct-type intraductal papillary mucinous neoplasms



British Journal of Surgery 101(6): 686-692



Classifications of intraductal papillary mucinous neoplasm (IPMN) remain ambiguous, especially for the mixed type. Factors predicting malignancy remain unclear. The aim of this study was to evaluate the usefulness of factors predicting malignancy in the new international consensus guidelines for resection of branch duct-type (BD)-IPMN and to compare them with those in the previous version. A prospectively collected database of patients with biopsy-proven BD-IPMN was analysed to compare factors between the first and second consensus guidelines, particularly as predictors of malignancy. Of 350 patients with BD-IPMN, sensitivity (0.724) and balanced accuracy (0.751) of the second guidelines were superior to those (0.639 and 0.730) in the first version at the expense of slightly reduced specificity (0.779 versus 0.822 for the first version) by random forest models. Multiple logistic regression analysis showed that main pancreatic duct dilatation greater than 5 mm (hazard ratio (HR) 4.54, 95 per cent confidence interval 2.45 to 8.41; P < 0.001), mural nodules (HR 6.27, 3.27 to 12.01; P < 0.001) and carbohydrate antigen 19-9 level above 37 units/ml (HR 4.03, 1.83 to 8.90; P = 0.001) were independent predictors of BD-IPMN malignancy. The new consensus guidelines provide better sensitivity, performance of factors predicting malignancy, and balanced accuracy in the diagnosis of BD-IPMN malignancy. Size alone was limited in predicting malignancy. Variability in clinical significance of the individual factors associated with a risk of malignancy indicates the need for a tailored approach in the management of patients with BD-IPMN.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 056836461

Download citation: RISBibTeXText

PMID: 24668442

DOI: 10.1002/bjs.9491


Related references

Validation of the 2012 International Consensus Guidelines Using CT and MRI: Branch Duct and Main Duct Intraductal Papillary Mucinous Neoplasms of the Pancreas. Annals of Surgery 266(6): E51-E52, 2017

Single-institution validation of the international consensus guidelines for treatment of branch duct intraductal papillary mucinous neoplasms of the pancreas. Journal of Hepato-Biliary-Pancreatic Surgery 16(3): 353-358, 2009

Tu1510 Validation of the International Consensus Guidelines for Branch Duct Intraductal Papillary Mucinous Neoplasms of the Pancreas: A Meta-Analysis. Gastroenterology 142(5): S-852-S-853, 2012

Validation of the 2012 International Consensus Guidelines Using Computed Tomography and Magnetic Resonance Imaging: Branch Duct and Main Duct Intraductal Papillary Mucinous Neoplasms of the Pancreas. Annals of Surgery 263(3): 557-564, 2016

Accuracy of 2012 International Consensus Guidelines for the prediction of malignancy of branch-duct intraductal papillary mucinous neoplasms of the pancreas. United European Gastroenterology Journal 4(4): 580-586, 2016

Pancreatic-duct-lavage cytology in candidates for surgical resection of branch-duct intraductal papillary mucinous neoplasm of the pancreas: should the International Consensus Guidelines be revised?. Gastrointestinal Endoscopy 69(3 Pt 1): 434-440, 2008

"High-risk stigmata" of the 2012 international consensus guidelines correlate with the malignant grade of branch duct intraductal papillary mucinous neoplasms of the pancreas. Pancreas 43(8): 1239-1243, 2015

Branch duct intraductal papillary mucinous neoplasms: does cyst size change the tip of the scale? A critical analysis of the revised international consensus guidelines in a large single-institutional series. Annals of Surgery 258(3): 466-475, 2013

Cyst fluid biomarkers for intraductal papillary mucinous neoplasms of the pancreas: a critical review from the international expert meeting on pancreatic branch-duct-intraductal papillary mucinous neoplasms. Journal of the American College of Surgeons 220(2): 243-253, 2015

Utility of the sendai consensus guidelines for branch-duct intraductal papillary mucinous neoplasms: a systematic review. Journal of Gastrointestinal Surgery 18(7): 1350-1357, 2015

S1297 When to Operate or Observe Branch Duct Intraductal Papillary Mucinous Neoplasms (Ipmn-Br): Evaluation of Consensus Guidelines. Gastroenterology 136(5): A-232, 2009

Evaluation of the International Consensus Guidelines for the Surgical Resection of Intraductal Papillary Mucinous Neoplasms. Digestive Diseases and Sciences 63(4): 860-867, 2017

Treatment guidelines for branch duct type intraductal papillary mucinous neoplasms of the pancreas: when can we operate or observe?. Annals of Surgical Oncology 15(1): 199-205, 2007

International Consensus Guidelines for Management of Intraductal Papillary Mucinous Neoplasms and Mucinous Cystic Neoplasms of the Pancreas. Pancreatology 6(1-2): 17-32, 2006

Which guidelines should be used for branch-duct intraductal papillary mucinous neoplasms?. Gastrointestinal Endoscopy 84(3): 446-449, 2017